Scheen, André J.
Article History
First Online: 22 March 2020
Compliance with Ethical Standards
:
: No sources of funding were used to assist in the preparation of this article.
: André J. Scheen has no conflicts of interest that are directly relevant to the content of this article. He has received lecturer/scientific advisor/clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, NovoNordisk, Sanofi-Aventis and Servier and has worked as a clinical investigator in EMPA-REG OUTCOME, CANVAS-R and DECLARE-TIMI 58 cardiovascular outcome trials.